| CAS NO: | 17230-88-5 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Cas No. | 17230-88-5 |
| 别名 | 达那唑 |
| 化学名 | pregna-2,4-dien-20-yno[2,3-d]isoxazol-17α-ol |
| Canonical SMILES | O[C@@]1(C#C)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C |
| 分子式 | C22H27NO2 |
| 分子量 | 337.5 |
| 溶解度 | ≥ 11.05 mg/mL in DMSO, ≥ 14.84 mg/mL in EtOH with ultrasonic |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Danazol showed weak androgenic effects. Danazol is a derivative of testosterone and ethisterone. An androgen is any natural or synthetic agent stimulating or controling the development and maintenance of male characteristics by binding to androgen receptors. This includes the activity of the primary male sex organs and development of male secondary sex characteristics. In vitro: Previous study found that danazol as low as 1 micrometer could suppress LH-stimulated testosterone and androstenedione production in cultured Leydig cells. The addition of danazol to a preparation of testicular microsomes elicited a type I cytochrome P-450 binding spectrum. Danazol could inhibit progesterone and 17alpha-hydroxy-progesterone binding to microsomal P-450 [1]. In vivo: The purpose of a previous study was to examine the role of androgen and estrogen receptors in danazol suppression of luteinizing hormone (LH) in the rat. The estrogen receptor antagonist, LY 156758, partially antagonized the suppressed levels of LH after administration of danazol to ovariectomized rats. In contrast, the androgen receptor antagonist, flutamide, had no effect on suppressed LH levels after danazol treatment, but did partially reverse the inhibition of LH 24 hr after danazol administration to ovariectomized rats [2]. Clinical trial: Danazol was administered to patients with advanced prostate cancer for periods ranging from 3 days to 18 weeks. There were no objective remissions, but three patients had objectively stable disease with complete pain control for periods ranging 15-18 weeks. Seven patients experienced tumor flare reactions, one requiring withdrawal of treatment and one resulting in rapid clinical deterioration and death. Four other patients died within 3 weeks [3]. References: |
m.cnreagent.com